Vividion Therapeutics names Jenna Goldberg as Chief Medical Officer
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Jenna Goldberg, M.D., has joined the company as Chief Medical Officer.
Read more ...
Bayer with continued strong performance
The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we were again able to boost sales and earnings," said Werner Baumann, Chairman of the Board of Management, when presenting the company's quarterly statement on Tuesday.
Read more ...
Pfizer's elranatamab granted FDA Breakthrough Therapy Designation for relapsed or refractory multiple myeloma
Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM). Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb).
Read more ...
Salvat Laboratories announces submission of New Drug Application to the U.S. FDA for Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery
Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients.
This submission comes after two successful phase III clinical trials conducted between 2020 and 2021.
Pfizer and BioNTech announce positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster in individuals 18 years and older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the safety, tolerability, and immunogenicity of the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)).
Read more ...
Bayer signs grant agreement to advance innovation in non-hormonal contraception
Bayer announced that it has received a grant from the Bill & Melinda Gates Foundation. As part of the grant, Bayer and the Bill & Melinda Gates Foundation have each committed more than US$ 12 million over four years to co-fund pre-clinical research activities with the goal of providing women globally with an option for non-hormonal contraception.
Read more ...
GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D
GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK with access to Tempus' AI-enabled platform, including its library of de-identified patient data. Through its leading Artificial Intelligence and Machine Learning (AI/ML) capability, GSK will work together with Tempus to improve clinical trial design, speed up enrolment and identify drug targets.
Read more ...